Merck, HPV vaccine and Cervical cancer
Merck Gets FDA Priority Review of Welireg
In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.
In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently discussed. In his latest appearance on CNBC’s Squawk on the ...
Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...
Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Visitors can capture their photos with the Red Card at the stand to contribute to a powerful visual Mosaic symbol of ...
We recently published a list of 12 Best Dow Stocks to Buy Right Now. In this article, we are going to take a look at where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback